Previous New Releases from NCBI BookshelfSotatercept (Winrevair): Indication: In combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization Group 1 PAH and Functional Class II or III: Reimbursement Recommendation [Internet].Sotatercept (Winrevair): Indication: In combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization Group 1 PAH and Functional Class II or III: Reimbursement Recommendation [Internet].